Which
oral drug for treating hyperglycemia can delay the absorption of
carbohydrate and lower postprandial glycemic excursion: (
)
A: Sulfonylureas
B: Metformin
C: Acarbose
D: Insulin
E: Thiazolidinediones
oral drug for treating hyperglycemia can delay the absorption of
carbohydrate and lower postprandial glycemic excursion: (
)
A: Sulfonylureas
B: Metformin
C: Acarbose
D: Insulin
E: Thiazolidinediones
举一反三
- Oral<br/>hypoglycemic agents EXCEPT() A: Sulfonylureas B: Biguanides C: Thiazolidinediones D: Insulin E: α-glucosidase inhibitors
- Carbohydrate<br/>having high glycemic index leads to () A: obesity B: insulin<br/>resistance C: diabetes<br/>mellitus type 2 D: all<br/>of the above
- The<br/>bioavailability is() A: the<br/>quantity of drug absorbed after oral administration B: the<br/>rate of drug absorbed after oral administration C: the<br/>ratio of AUC(oral)/AUC(intravenous) D: the<br/>ratio of AUC (intravenous)/AUC(oral) E: the<br/>area under curve of oral administration
- The<br/>crude drug which has the effects of“moderating drug” is<br/>____. A: Rhubarb B: Clove C: Senna<br/>Leaf D: Licorice<br/>Root E: Ginseng
- In<br/>terms of bioavailability, the following statements are true() A: The<br/>amount of a drug absorbed into the bloodstream B: The<br/>total amount of drug in the body at peak concentration C: The<br/>total amount of drug in the body at a steady-state concentration D: The<br/>amount and rate at which a drug is absorbed into the systemic<br/>circulation E: The<br/>amount of drug that passes through the gastrointestinal tract into<br/>the hepatic portal vein